Table 5 Platelet transfusion exposure in... | American Society of Hematology

Table 5

Platelet transfusion exposure in patients with criteria for treatment-emergent ALI and ARDS

	Treatment group		Total
	Test	Reference	Total
Patients With ALI (N)*	19	16	35
Mean duration of platelet support in days (SD)	15.6 (9.2)	17.4 (8.5)	16.5 (8.8)
Mean total platelet transfusions (SD)	16.1 (12.4)	16.3 (9.5)	16.2 (11.0)
Patients With ARDS (N)†	12	5	17
Mean duration of platelet support in days (SD)	18.3 (9.6)	10.6 (5.6)	16.1 (10.9)
Mean total platelet transfusions (SD)	19.4 (13.4)	11.4 (7.8)	17.1 (12.4)

	Treatment group		Total
	Test	Reference	Total
Patients With ALI (N)*	19	16	35
Mean duration of platelet support in days (SD)	15.6 (9.2)	17.4 (8.5)	16.5 (8.8)
Mean total platelet transfusions (SD)	16.1 (12.4)	16.3 (9.5)	16.2 (11.0)
Patients With ARDS (N)†	12	5	17
Mean duration of platelet support in days (SD)	18.3 (9.6)	10.6 (5.6)	16.1 (10.9)
Mean total platelet transfusions (SD)	19.4 (13.4)	11.4 (7.8)	17.1 (12.4)

Patients with AECC criteria and a PaO₂/FiO₂ ratio < 300.

Patients with AECC criteria and a PaO₂/FiO₂ ratio < 200.